Research graph
References from A Case of Acute Mania and Rhabdomyolysis Associated With Long-Term, Daily Psilocybin Use. Local targets link to admitted publications; unresolved targets remain external evidence.
Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers’ Task Group on Psychedelics and Related Compounds
10.1016/j.eclinm.2025.103517 · 2025 · External reference
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
10.1016/j.neuropharm.2017.12.041 · 2018 · External reference
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
10.1177/0269881114548296 · 2014 · External reference
Drug–drug interactions involving classic psychedelics: a systematic review
10.1177/02698811231211219 · 2024 · External reference
Trial of psilocybin versus escitalopram for depression
10.1056/nejmoa2032994 · 2021 · External reference
Rise of the mushrooms: effects of psilocybin reforms on psychedelic usage patterns
10.1177/07439156251360774 · 2026 · External reference
Psychedelic drug legislative reform and legalization in the US
10.1001/jamapsychiatry.2022.4101 · 2023 · External reference
Psilocybin trends in states that decriminalized use
10.1001/jama.2026.1952 · 2026 · External reference
Psilocybin dispensaries and online health claims in Canada
10.1001/jamanetworkopen.2025.2853 · 2025 · External reference
Microdosing psychedelics: current evidence from controlled studies
2024 · External reference
A case report of psilocybin-induced psychosis in a predisposed patient
10.9758/cpn.24.1180 · 2024 · External reference
The many faces of psilocybin-related psychosis: a case series
2025 · External reference
Wild-mushroom intoxication as a cause of rhabdomyolysis
10.1056/nejmoa010581 · 2001 · External reference
A method for estimating the probability of adverse drug reactions
10.1038/clpt.1981.154 · 1981 · External reference
Psilocybin trends in states that decriminalized use
10.1001/jama.2026.1952 · ExternalCitation · doi-reference
Psilocybin dispensaries and online health claims in Canada
10.1001/jamanetworkopen.2025.2853 · ExternalCitation · doi-reference
Psychedelic drug legislative reform and legalization in the US
10.1001/jamapsychiatry.2022.4101 · ExternalCitation · doi-reference
Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers’ Task Group on Psychedelics and Related Compounds
10.1016/j.eclinm.2025.103517 · ExternalCitation · doi-reference
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
10.1016/j.neuropharm.2017.12.041 · ExternalCitation · doi-reference
A method for estimating the probability of adverse drug reactions
10.1038/clpt.1981.154 · ExternalCitation · doi-reference
Wild-mushroom intoxication as a cause of rhabdomyolysis
10.1056/nejmoa010581 · ExternalCitation · doi-reference
Trial of psilocybin versus escitalopram for depression
10.1056/nejmoa2032994 · ExternalCitation · doi-reference
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
10.1177/0269881114548296 · ExternalCitation · doi-reference
Drug–drug interactions involving classic psychedelics: a systematic review
10.1177/02698811231211219 · ExternalCitation · doi-reference
Rise of the mushrooms: effects of psilocybin reforms on psychedelic usage patterns
10.1177/07439156251360774 · ExternalCitation · doi-reference
A case report of psilocybin-induced psychosis in a predisposed patient
10.9758/cpn.24.1180 · ExternalCitation · doi-reference
